Companies NGM Biopharmaceuticals
NGM Biopharmaceuticals (NGM): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
NGM Biopharmaceuticals no longer files a proxy statement; its last pay data is FY2022.
CEO vs. named peers60th pct.Of 21 peer CEOs
CEO pay, last three years
- $4,559,630FY2020
- $9,911,980FY2021
- $5,933,500FY2022
CEO total pay was $5,933,500 in fiscal 2022, down from $9,911,980 in fiscal 2021.
FY2022: salary $610,000 · bonus $0 · stock awards $0 · option awards $5,072,750
Frequently asked questions
Who was the highest-paid executive at NGM Biopharmaceuticals in fiscal 2022?
As disclosed, David Woodhouse (Chief Executive Officer) was the highest-paid executive at NGM Biopharmaceuticals in fiscal 2022, with total compensation of $5,933,500.
How does NGM Biopharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, David Woodhouse's total compensation ranked at the 60th percentile of NGM Biopharmaceuticals's disclosed peer group.
What is NGM Biopharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, NGM Biopharmaceuticals's CEO-to-median employee pay ratio was 24:1.
How did shareholders vote on NGM Biopharmaceuticals's executive compensation?
As disclosed, 97.67% of shareholders supported NGM Biopharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does NGM Biopharmaceuticals spend in total on board compensation for fiscal 2022?
As disclosed, NGM Biopharmaceuticals reported total board compensation of $1,434,449 for fiscal 2022.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Woodhouse | $610,000 | $0 | $0 | $5,072,750 | $250,000 | $0 | $750 | $5,933,500 |
| Chief Executive Officer | ||||||||
| Siobhan Nolan Mangini | 480,000 | 0 | 0 | 2,903,030 | 150,000 | 0 | 750 | 3,533,780 |
| President and Chief Financial Officer | ||||||||
| Hsiao Lieu | 475,000 | 7,500 | 0 | 2,106,660 | 142,500 | 0 | 750 | 2,732,410 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Jin-Long Chen | 550,000 | 0 | 0 | 1,775,463 | 180,000 | 0 | 750 | 2,506,213 |
| Founder and Chief Scientific Officer | ||||||||
| Valerie Pierce | 440,000 | 8,000 | 0 | 1,521,825 | 132,000 | 0 | 750 | 2,102,575 |
| Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| David Woodhouse | $5,933,500 | $9,911,980 | $4,559,630 | ↓ −3,978,480 |
| Siobhan Nolan Mangini | 3,533,780 | 1,614,220 | 3,813,965 | ↑ +1,919,560 |
| Hsiao Lieu | 2,732,410 | 2,632,690 | 822,368 | ↑ +99,720 |
| Jin-Long Chen | 2,506,213 | 4,242,895 | 2,368,073 | ↓ −1,736,682 |
| Valerie Pierce | 2,102,575 | 2,589,690 | — | ↓ −487,115 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company structures executive compensation to reward and motivate officers who contribute to operational and strategic objectives, attract and retain talent, and link executive interests with stockholders through long-term equity incentives. A significant portion of target compensation is 'at-risk,' consisting of annual performance-based bonuses and equity awards, to align pay with both short- and long-term performance and stockholder value.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jin-Long Chen | OPTION | 2022-03-03 | — | — | 175,000 | — | $1,775,463 |
| Hsiao Lieu | OPTION | 2022-03-03 | — | — | 150,000 | — | 1,521,825 |
| Hsiao Lieu | OPTION | 2022-11-04 | — | — | 150,000 | — | 584,835 |
| Valerie Pierce | OPTION | 2022-03-03 | — | — | 150,000 | — | 1,521,825 |
| Siobhan Nolan Mangini | OPTION | 2022-07-01 | — | — | 100,000 | — | 873,930 |
| David Woodhouse | OPTION | 2022-03-03 | — | — | 500,000 | — | 5,072,750 |
| Siobhan Nolan Mangini | OPTION | 2022-03-03 | — | — | 200,000 | — | 2,029,100 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jin-Long Chen | $0 | $0 | $1,775,463 | 0.0% |
| Hsiao Lieu | 0 | 0 | 2,106,660 | 0.0% |
| Valerie Pierce | 0 | 0 | 1,521,825 | 0.0% |
| Siobhan Nolan Mangini | 0 | 0 | 2,903,030 | 0.0% |
| David Woodhouse | 0 | 0 | 5,072,750 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Siobhan Nolan Mangini | Option | 26,042 | 31.93 | — |
| Hsiao Lieu | Option | 52,084 | 31.93 | — |
| Valerie Pierce | Option | 52,084 | 31.93 | — |
| Siobhan Nolan Mangini | Option | 89,584 | 12.78 | — |
| Jin-Long Chen | Option | 91,146 | 31.93 | — |
| Hsiao Lieu | Option | 115,625 | 15.2 | — |
| Valerie Pierce | Option | 115,625 | 15.2 | — |
| Jin-Long Chen | Option | 134,896 | 15.2 | — |
| Hsiao Lieu | Option | 150,000 | 5.36 | — |
| Siobhan Nolan Mangini | Option | 154,167 | 15.2 | — |
| David Woodhouse | Option | 234,375 | 31.93 | — |
| David Woodhouse | Option | 385,417 | 15.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William J. RieflinNot independent · Board Chair | $37,500 | $0 | $0 | — | $1,067,350 | $1,104,850 |
| Shelly D. GuyerIndependent · Audit (Chair) · Nominating and Corporate Governance | 73,091 | 0 | 200,001 | — | 0 | 273,092 |
| David V. Goeddel, Ph.DIndependent · Lead Independent Director · Nominating and Corporate Governance | 70,233 | 0 | 200,001 | — | 0 | 270,234 |
| Suzanne Sawochka HooperIndependent · Audit · Compensation (Chair) | 65,000 | 0 | 200,001 | — | 0 | 265,001 |
| Carole Ho, M.DIndependent · Audit · Compensation | 52,181 | 0 | 200,001 | — | 0 | 252,182 |
| Roger M. Perlmutter, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) | 50,000 | 0 | 200,001 | — | 0 | 250,001 |
| Mark LeschlyIndependent · Departed during FY | 19,094 | 0 | 0 | — | 0 | 19,094 |
| Jin-Long Chen, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| David J. Woodhouse, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $367,099 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $1,067,350 |
| Total cost of the board | $1,434,449 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names NGM Biopharmaceuticals as a peer
Companies that benchmark against NGM
1 company names NGM as a compensation peer
- Azenta, Inc.AZTAFY2025
Each company listed discloses NGM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NGM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
KOD Kodiak Sciences Inc.RCUS Arcus Biosciences, Inc.CYTK Cytokinetics, IncorporatedRLAY Turning Point Therapeutics, Inc.ALEC Alector, Inc.ALLK Allakos Inc.ALLO Allogene Therapeutics, Inc.ANAB AnaptysBio, Inc.APLS Apellis Pharmaceuticals, Inc.ARCT Arcturus Therapeutics Holdings, Inc.ATRA Atara Biotherapeutics, Inc.CTMX CytomX Therapeutics, Inc.DNLI Denali Therapeutics Inc.AGIO Dicerna Pharmaceuticals, Inc.EDIT Editas Medicine, Inc.MRSN Forma Therapeutics Holdings, Inc.GOSS Gossamer Bio, Inc.MDGL Madrigal Pharmaceuticals, Inc.REPL Replimune Group, Inc. Rubius Therapeutics, Inc.SRRK Scholar Rock Holding Corporation
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | Cytokinetics, Incorporated | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 4 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 5 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 6 | Allakos Inc. | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 7 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 8 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 9 | NGM Biopharmaceuticals | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 10 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 11 | Dicerna Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 12 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 13 | CytomX Therapeutics, Inc. | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 14 | Turning Point Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 15 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 16 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 17 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 18 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 19 | Arcturus Therapeutics Holdings, Inc. | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 20 | Forma Therapeutics Holdings, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 21 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| NGM Biopharmaceuticals | 75% | Option 100 | not disclosed | Aon |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos Inc. | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcturus Therapeutics Holdings, Inc. | not disclosed | Options 100 | not disclosed | not disclosed |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Cytokinetics, Incorporated | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| CytomX Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Dicerna Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Forma Therapeutics Holdings, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Kodiak Sciences Inc. | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Turning Point Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-05-10 | 60,368,696 | 1,409,151 | 31,238 | 97.67% | Passed |
| 2022 | 2022-05-18 | 48,944,032 | 15,300,203 | 32,652 | 76.18% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-05-10 | 97.67%a |
| 2022 | 2022-05-18 | 76.18%b |
a. Approved under the standard stated in the filing — “Majority of the voting power of the shares present or represented by proxy and entitled to vote generally on the subject matter; of the shares present and entitled to vote on the proposal, a majority of them must be voted "FOR" the proposal for it to be approved. | Abstentions: An abstention will have the same effect as a vote "AGAINST" the proposal.”.
b. Approved under the standard stated in the filing — “Majority of the votes cast; shares voted "FOR" the proposal must exceed the number of shares voted "AGAINST" the proposal. | Abstentions: No effect. An abstention does not count as a vote cast.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 24 : 1 |
|---|---|
| CEO total compensation | $5,933,500 |
| Median employee compensation | $251,078 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Woodhouse | Director | 2023-11-06 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 57,833 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 87,013 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | D | 190,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | A | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | A | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | A | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | A | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | A | 190,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 57,833 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 87,013 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | A | 255,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | A | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2023-11-06 | A | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | A | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2023-11-06 | A | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2023-11-06 | D | 255,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | A | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2023-11-06 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2023-11-15 | A | 16,791 | 1 | 11,880 | Common | Form 4 ↗ |
| David Goeddel V | Director | 2023-11-15 | A | 2,720 | 1 | 1,919 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-15 | A | 16,791 | 1 | 11,880 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-15 | A | 16,791 | 1 | 11,880 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-15 | A | 16,791 | 1 | 11,880 | Common | Form 4 ↗ |
| David Goeddel V | Director | 2023-11-16 | A | 5,840 | 1 | 3,627 | Common | Form 4 ↗ |
| David Goeddel V | Director | 2023-11-16 | A | 1,460 | 1 | 907 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-16 | A | 5,840 | 1 | 3,627 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-16 | A | 5,840 | 1 | 3,627 | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2023-11-16 | A | 5,840 | 1 | 3,627 | Common | Form 4 ↗ |
| Jean-Frederic Viret | Chief Financial Officer | 2023-12-01 | A | 450,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | EVP, Chief Medical Officer | 2024-01-16 | D | 5,430 | 1 | 7,276 | Common | Form 4 ↗ |
| Valerie Pierce | SVP, GC & CCO | 2024-01-16 | D | 5,021 | 1 | 6,728 | Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-01-16 | D | 13,032 | 1 | 17,463 | Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-01-16 | D | 1,025 | 1 | 1,374 | Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 381,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 57,833 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 87,013 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 255,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 95,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 97,654 | — | — | Common | Form 4 ↗ |
| David Woodhouse | Director | 2024-04-05 | D | 23,993 | — | — | Common | Form 4 ↗ |
| Shelly D. Guyer | Director | 2024-04-05 | D | 49,197 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shelly D. Guyer | Director | 2024-04-05 | D | 16,806 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shelly D. Guyer | Director | 2024-04-05 | D | 19,619 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shelly D. Guyer | Director | 2024-04-05 | D | 24,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shelly D. Guyer | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 38,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 16,806 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 19,619 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 24,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 190,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 39,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 19,349 | — | — | Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 147,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 36,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Valerie Pierce | See Remarks | 2024-04-05 | D | 26,458 | — | — | Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 7,000 | — | — | Common | Form 4 ↗ |
| Hsiao Lieu | Chief Medical Officer | 2024-04-05 | D | 159,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Roger M. Perlmutter | Director | 2024-04-05 | D | 46,238 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Roger M. Perlmutter | Director | 2024-04-05 | D | 24,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Roger M. Perlmutter | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Sawochka Hooper | Director | 2024-04-05 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carole Ho | Director | 2024-04-05 | D | 39,515 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carole Ho | Director | 2024-04-05 | D | 19,619 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carole Ho | Director | 2024-04-05 | D | 24,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carole Ho | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 17,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 35,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 7,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Perlich | Principal Accounting Officer | 2024-04-05 | D | 6,284 | — | — | Common | Form 4 ↗ |
| Jean-Frederic Viret | Chief Financial Officer | 2024-04-05 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jean-Frederic Viret | Chief Financial Officer | 2024-04-05 | D | 3,038 | — | — | Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 2,769,168 | — | — | Common | Form 4 ↗ |
| William J. Rieflin | Director | 2024-04-05 | D | 5,172 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 16,806 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 19,619 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 24,222 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 78,407 | — | — | Derivative, Class A Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | A | 1,000 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 2,265,758 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 968,990 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 858,035 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 11,103,333 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 90,442 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 2,650,177 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 949,862 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 190,000 | — | — | Common | Form 4 ↗ |
| David Goeddel V | Director | 2024-04-05 | D | 134,180 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | A | 1,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 44,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 15,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 2,265,758 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 968,990 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 858,035 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 11,103,333 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 90,442 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 2,650,177 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP L P | Director | 2024-04-05 | D | 949,862 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | A | 1,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 44,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 15,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 2,265,758 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 968,990 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 858,035 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 11,103,333 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 90,442 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 2,650,177 | — | — | Common | Form 4 ↗ |
| COLUMN GROUP GP, LP | Greater-than-10% holder | 2024-04-05 | D | 949,862 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | A | 1,000 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 44,000 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 15,000 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 100,000 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 1,298,908 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 2,265,758 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 968,990 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 858,035 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 11,103,333 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 90,442 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 2,650,177 | — | — | Common | Form 4 ↗ |
| TCG Opportunity III GP, LLC | Greater-than-10% holder | 2024-04-05 | D | 949,862 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (227 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, David Woodhouse. DEF 14A, filed 2023-03-29. Section “Executive Compensation”. As printed: 5,933,500. View filing ↗
- Section 01, Siobhan Nolan Mangini. DEF 14A, filed 2023-03-29. Section “Summary Compensation Table”. As printed: 3,533,780. View filing ↗
- Section 01, Hsiao Lieu. DEF 14A, filed 2023-03-29. Section “Executive Compensation”. As printed: 2,732,410. View filing ↗
- Section 01, Jin-Long Chen. DEF 14A, filed 2023-03-29. Section “Executive Compensation”. As printed: 2,506,213. View filing ↗
- Section 01, Valerie Pierce. DEF 14A, filed 2023-03-29. Section “Executive Compensation”. As printed: 2,102,575. View filing ↗
- Section 03, Jin-Long Chen OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hsiao Lieu OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Hsiao Lieu OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Valerie Pierce OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Siobhan Nolan Mangini OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Woodhouse OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Siobhan Nolan Mangini OPTION. DEF 14A, filed 2023-03-29. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-03-29. Section “CEO Pay Ratio”. As printed: 24 : 1. View filing ↗
- Section 08, William J. Rieflin. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 1,104,850. View filing ↗
- Section 08, Shelly D. Guyer. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 273,092. View filing ↗
- Section 08, David V. Goeddel, Ph.D. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 270,234. View filing ↗
- Section 08, Suzanne Sawochka Hooper. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 265,001. View filing ↗
- Section 08, Carole Ho, M.D. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 252,182. View filing ↗
- Section 08, Roger M. Perlmutter, M.D., Ph.D. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 250,001. View filing ↗
- Section 08, Mark Leschly. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 19,094. View filing ↗
- Section 08, Jin-Long Chen, Ph.D. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, David J. Woodhouse, Ph.D. DEF 14A, filed 2023-03-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2023-11-06. Form 4, filed 2023-11-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2023-11-15. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2023-11-15. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-15. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-15. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-15. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2023-11-16. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2023-11-16. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-16. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-16. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2023-11-16. Form 4, filed 2023-11-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jean-Frederic Viret 2023-12-01. Form 4, filed 2023-12-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Woodhouse 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelly D. Guyer 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelly D. Guyer 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelly D. Guyer 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelly D. Guyer 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelly D. Guyer 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Valerie Pierce 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hsiao Lieu 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger M. Perlmutter 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger M. Perlmutter 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Roger M. Perlmutter 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Sawochka Hooper 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carole Ho 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carole Ho 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carole Ho 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carole Ho 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Perlich 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jean-Frederic Viret 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jean-Frederic Viret 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William J. Rieflin 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Goeddel V 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP L P 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, COLUMN GROUP GP, LP 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TCG Opportunity III GP, LLC 2024-04-05. Form 4, filed 2024-04-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-12. Item 5.07 · say-on-pay result. As reported: 97.67% (votes for as printed: 60,368,696). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-24. Item 5.07 · say-on-pay result. As reported: 76.18% (votes for as printed: 48,944,032). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 367,099 + equity 0 + all other 1,067,350 = 1,434,449, summed across the director compensation table rows.
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- Cytokinetics, Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics, Incorporated's own proxy. As printed: 11,881,456. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Allakos Inc., Section 10b CEO total. DEF 14A, filed 2024-04-23. CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- NGM Biopharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2023-03-29. CEO total compensation as printed in NGM Biopharmaceuticals's own proxy. As printed: 5,933,500. View filing ↗
- Replimune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- Dicerna Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Dicerna Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- CytomX Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics, Inc.'s own proxy. As printed: 4,738,495. View filing ↗
- Turning Point Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Turning Point Therapeutics, Inc.'s own proxy. As printed: 4,646,454. View filing ↗
- Kodiak Sciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Arcturus Therapeutics Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Arcturus Therapeutics Holdings, Inc.'s own proxy. As printed: 1,691,000. View filing ↗
- Forma Therapeutics Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Forma Therapeutics Holdings, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗